Javier Botín takes control of Sesderma in deal valued near €150M
What's the deal? Javier Botín has taken control of SesdermaDealroom has a profile for this one. Try Dealroom →, the Valencia-based dermocosmetics company founded by dermatologist Gabriel SerranoDealroom has a profile for this one. Try Dealroom →. Botín's firm, JB CapitalDealroom has a profile for this one. Try Dealroom →, entered with 50% of the capital and assumes management control, while Serrano exits the company. Market reports value the transaction at around €150 million, though the parties have not disclosed terms.
Why now? The move follows a complex stretch for Sesderma, which spent months refinancing its debt and seeking an investor to provide financial stability. JB Capital's entry ends that process and gives the firm a capital structure to fund its next phase.
What each side brings: Founded in 1989, Sesderma is one of Spain's best-known skincare brands, built on scientific research and a strong presence in the pharmacy channel across dozens of international markets. For Botín — youngest child of the late banker Emilio Botín and brother of SantanderDealroom has a profile for this one. Try Dealroom → chair Ana BotínDealroom has a profile for this one. Try Dealroom → — the deal adds a consolidated brand to a portfolio and deepens JB Capital's presence in health and consumer sectors.
What's the endgame? The priority now is accelerating growth without losing the scientific edge that has defined Sesderma for over three decades. Internationalisation, new product lines, and stronger innovation capacity top the agenda for the new chapter.
What could go wrong? The founder's departure removes the figure who built the brand's scientific identity. Balancing faster expansion against that research-led positioning is the central challenge.
The signal: The deal is one of the largest in Spain's dermocosmetics industry in 2026 and confirms investor appetite for Spanish brands with international reach. Health, wellness, and beauty continue to draw capital, lifted by an ageing population and rising demand for high-value skincare.
Read more: Forbes España
